Journal
AMERICAN JOURNAL OF ROENTGENOLOGY
Volume 199, Issue 1, Pages 58-64Publisher
AMER ROENTGEN RAY SOC
DOI: 10.2214/AJR.11.7432
Keywords
abdominal toxicities; bevacizumab; drug; molecular targeted therapy; targeted therapy; toxicity
Ask authors/readers for more resources
OBJECTIVE. Novel drugs targeting molecular pathways involved in tumor development have revolutionized cancer treatment. Radiologists often focus on therapeutic response when evaluating cancer patients and may miss important signs of drug toxicity. This article familiarizes radiologists with the complications of molecular targeted agents in abdominal solid organs, enabling early identification and appropriate intervention and thus reducing patient morbidity and mortality. CONCLUSION. Knowledge of the common abdominal toxicities-including hepatitis, cholecystitis, pancreatitis, fluid retention, and infection-is crucial for early diagnosis, which may spare patients devastating complications or the need for surgery.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available